Articles tagged with Weight Gain
CBL-514 selectively induces apoptosis of fat cells, reducing subcutaneous and visceral fat volume by 10.45% and 22.21% respectively in phase 2 clinical trials. The drug was well-tolerated with mostly mild-to-moderate injection-site reactions.
Researchers found trevogrumab significantly reduced lean mass loss by 50% when used with semaglutide. Participants who received trevogrumab experienced a mean increase in lean mass of +0.4%, while those who received placebo experienced a mean decrease of -2.4%.
Research in the American Journal of Preventive Medicine suggests that mothers with poor sleep quality in late pregnancy had babies with lower weight in the first 6 months of life, but higher weight after age 1-2 years. This effect was strongest in male infants and in babies born at term.
Digital behavioral infrastructure leverages digital health apps to drive medication persistence, side-effect mitigation, and durable weight loss. The 'habit window' hypothesis proposes building healthy behaviors during medication's peak efficacy window.
A recent study identified three distinct BMI trajectories among people with type 2 diabetes, with stable, increasing, and decreasing trajectories associated with different comorbidities and healthcare service use. Increasing BMI was linked to a clustering of chronic diseases, while weight loss was not always indicative of better health...
A case-control study found that patients with overweight or obesity at diagnosis had better survival rates than those with normal weight. However, the apparent advantage was largely due to prediagnostic weight loss associated with cancer, and should not be taken as evidence for weight gain in healthy individuals.
A new study published in JACC suggests that waist circumference and waist-to-hip ratio provide critical information about cardiovascular risk, even among people with a normal BMI. Individuals with elevated central adiposity were associated with higher risks for most outcomes, regardless of their weight status.
Adults with type 2 diabetes have a high risk of fragility fractures, but new research found GLP-1 receptor agonists reduce this risk by 21% compared to DPP-4 inhibitors. The largest reductions occurred in hip, femur, and spine fractures.
A noninferiority randomized clinical trial found that an alternative first-line regimen containing doravirine, lamivudine, and tenofovir disoproxil fumarate produced less weight gain than a combination of dolutegravir, emtricitabine, and tenofovir alafenamide. The regimen was noninferior for viral suppression at 48 weeks.
Researchers identified endotrophin as a biological marker that rises and falls with changes in body fat, reflecting changes in metabolic health. The study suggests endotrophin could serve as a valuable biomarker and therapeutic target for reducing obesity-related health risks.
Researchers from Pennington Biomedical will present findings on organoid models, GLP-1 therapies, and early-life nutrition. The center's broad research portfolio is represented at the annual meeting of the American Society for Nutrition.
Repeatedly losing and gaining weight accelerates muscle loss in middle-aged people, as found in new UC San Francisco research. The study analyzed MRI scans of 1,433 participants and found that those with fluctuating weights lost nearly four times as much thigh muscle over four years.
A new study published in the Journal of the Academy of Nutrition and Dietetics identifies chrononutrition as a viable approach for postpartum weight loss. The research found that time-based eating approaches, such as time-restricted eating, can be an effective strategy for mild calorie restriction and cardiometabolic health postpartum.
Research at Columbia University Irving Medical Center found that people who got 5-6 hours of sleep a night gained an average of one pound over six weeks, with increased sedentary time. This study suggests that getting adequate sleep may help reduce the risk of weight gain and obesity-related conditions.
A pooled analysis of two randomized trials found that decreasing sleep by just 1.5 hours each night was associated with increases in body weight, waist circumference, and sedentary time in adults with elevated cardiometabolic risk. The findings highlight the importance of discussing sleep duration at health care visits.
A review of research on repeated weight loss and regain suggests that yo-yo dieting is not necessarily as harmful as often portrayed. The benefits of weight loss can outweigh the potential risks of later weight regain, with several large studies showing that obesity itself is a primary driver of metabolic disease risk.
A recent study found that maternal obesity and excessive pregnancy weight gain significantly increased the risk of childhood obesity by age 3. Researchers tracked nearly 3,000 mother-child pairs and discovered that excess pregnancy weight gain was common, affecting about four in 10 mothers.
A new study reveals how Philip Morris Companies Inc. used cigarette research and flavor engineering to design Lunchables, a successful ultra-processed food for children. The company's strategy was based on optimizing 'technical synergies' between tobacco and food divisions.
Researchers at NIH have discovered key intracellular signaling processes involved in the weight-loss effects of semaglutide, a GLP-1 drug. The findings may help extend treatment duration and reduce plateaus experienced by patients.
A study published in Proceedings of the Royal Society B found that Azara's owl monkeys have gained an average of 4% weight over two decades due to rising temperatures, contradicting Bergmann's rule. The researchers suggest that warmer temperatures may have allowed young monkeys to invest extra energy in growth
Research by Dr. Hanim Diktas at Pennington Biomedical Research Center shows that combining GLP-1 receptor agonists with behavioral intervention leads to a greater reduction in 'food noise', a persistent thought about food disrupting daily life and healthy behaviors. The study found significant decreases in food noise for participants u...
Patients on tirzepatide at maximum dose have seven times higher odds of maintaining weight loss compared to those who stop treatment. Those on the lower 5mg dose have four times higher odds, according to a new study published in The Lancet.
New research finds that participants in the ATTAIN-MAINTAIN trial maintained a significant percentage of weight loss when switched from injectable tirzepatide or semaglutide to daily oral orforglipron treatment. The study shows that nearly all weight loss achieved on injectable therapies can be maintained by switching to oral therapies.
A new procedure, duodenal mucosal resurfacing, has shown promising results in preventing weight regain after GLP-1 therapy discontinuation. The study found that patients who underwent the procedure maintained over 80% of their weight loss and regained less weight compared to those who received a sham procedure.
A new study has found that postmenopausal white women with higher genetic risk of obesity regained weight about two times faster than those with lower genetic risk. Despite this difference, Black women in the study regained weight at a similar rate, regardless of their genetic risk.
A cluster-randomized trial found that an adaptive mobile health intervention effectively reduced the rate of gestational weight gain and total gestational weight gain among pregnant patients with overweight or obesity. The study suggests that technology-based interventions can be a valuable tool in managing excess weight during pregnancy.
A Cleveland Clinic analysis of nearly 8,000 patients found that discontinuing semaglutide and tirzepatide does not lead to significant weight regain in clinical practice. Many patients successfully stabilized their weight after one year through alternative treatments and therapeutic lifestyle interventions.
A $3.4 million NIH grant will fund a semi-automated feedback system to support people tracking diet, exercise, and weight in weight-management programs. The system aims to provide personalized feedback to increase tracking and weight loss success.
A large cohort study found that fewer than 1 in 4 adults with overweight or obesity without diabetes remained on GLP-1RA treatment after 12 months. Treatment switching between GLP-1RA agents was common, reflecting active therapy management and the emergence of new formulations and weight management agents.
Patients who stop taking weight loss drugs like Ozempic and Wegovy experience rapid weight regain of up to 60% within a year, but sustain around 25% of lost weight. Researchers found that individuals may maintain healthier eating habits even after treatment ends.
The study found excess adiposity remained highly prevalent among US youths in 2024, with certain racial and ethnic subgroups affected more. The prevalence of severe obesity was also higher for these subgroups.
Dr. Catherine Prater's research project aims to improve prediction models and uncover metabolic markers that explain individual differences in weight gain. She will use machine learning techniques to train and test prediction models using existing clinical trial data.
A systematic review finds that stopping weight loss drugs leads to rapid weight regain, reversing heart health markers in under two years. Average monthly weight gain is 0.4kg, with all cardiometabolic risk markers projected to return to pre-treatment levels within 1.4 years.
Researchers identified a specific type of gut bacteria, Turicibacter, that promotes metabolic health and reduces weight gain in mice. The bacterium produces fatty molecules that are absorbed by the small intestine, improving ceramide levels and preventing excessive weight gain.
A study found that women with obesity who stopped using GLP-1 receptor agonists experienced more gestational weight gain and a higher risk of preterm delivery, gestational diabetes, and hypertensive disorders. The research suggests that discontinuation of these medications may impact pregnancy outcomes.
Withdrawal of tirzepatide after 36-week treatment led to 25% or greater weight regain in most participants within a year, reversing initial cardiometabolic parameter improvements. Continued obesity treatment is crucial for sustained benefits.
A review of 1.6 million women found that two-thirds experience excessive or inadequate weight gain during pregnancy, associated with complications such as preterm birth and large birth weight. The study supports the development of global healthy growth and weight gain standards to improve outcomes for mothers and babies worldwide.
A study published in The Lancet Psychiatry found that metformin can help manage weight gain in overweight or obese youth taking medication for bipolar disorder, making it a potential standard of care treatment. The MOBILITY trial showed modest but significant benefits of metformin over no treatment, with well-tolerated side effects.
A doctor warns of critical treatment gaps in eating disorders, highlighting the dangers of ignoring physical warning signs and behavioral indicators. Dr. Jennifer Gaudiani advocates for integrated medical and psychological care to address the urgent need for effective treatment.
A culturally tailored community health worker intervention modestly lowered interdialytic weight gain and improved dialysis adherence among Hispanic and Latino patients with hemodialysis-dependent kidney failure. This study suggests that such interventions can enhance patient outcomes for these vulnerable populations.
A study by São Paulo State University found a direct association between adults' levels of physical activity and their children's sedentary behavior. Children of inactive parents tend to be more sedentary, but when mothers and fathers maintain an active routine, their children usually follow suit.
A recent study found that large portions of obesity-related conditions in US adolescents and young adults are attributable to obesity. Treating and preventing obesity may reduce these conditions and associated costs. The researchers emphasize the importance of addressing childhood obesity to prevent future health issues.
A new study found that excessive visceral fat is linked to faster ageing of the heart, with a genetic predisposition to female-type fat in women potentially slowing heart ageing. Researchers also discovered that artificial intelligence analysis of images revealed signs of organ ageing, including tissue stiffness and inflammation.
A telephone-based weight loss intervention significantly reduced weight in breast cancer patients with overweight and obesity. The study suggests that this intervention may improve disease outcomes, warranting further investigation in future trials.
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
A new study found that adolescents with higher blood levels of per- and polyfluoroalkyl substances (PFAS) prior to bariatric surgery regained more weight and had greater increases in waist circumference up to five years after surgery. Researchers believe PFAS exposure disrupts endocrine and metabolic processes, leading to weight regain.
A new genetic test can predict adulthood obesity in early childhood, allowing for targeted preventative strategies. The test was developed using data from over five million people and found to be twice as effective as previous tests at predicting obesity risk.
A meta-analysis published in BMC Medicine found that patients prescribed anti-obesity medications may experience a significant weight gain after stopping their prescription. The study analyzed data from 11 randomised trials and suggests that six approved anti-obesity medications are associated with weight regain after treatment cessation.
A study of 679 patients found that longer GLP-1RA treatment, not having diabetes, and higher body fat were associated with better weight reduction. Higher muscle mass and metabolic rate also contributed to successful weight loss in patients with overweight or obesity.
Sustained midlife weight loss was associated with lower chronic disease incidence and decreased all-cause mortality. The study's findings suggest that maintaining a healthy weight during middle age can have long-term health benefits.
GLP1-RA treatment is associated with improvements in quality of life, restrained eating, and emotional eating behavior. The treatment also provides reassurance regarding its psychiatric safety profile.
A Danish study found that adverse waist-to-height ratio trajectories in childhood are associated with increased cardiometabolic risk at age 10. Children with gradually increasing central obesity showed early signs of metabolic and cardiovascular risk, including elevated blood pressure and insulin resistance.
A child's body mass index (BMI) at six years old is a strong predictor of their risk of overweight or obesity at 18. Reaching a healthier weight before six can reduce this risk, but returning to it later does not have the same effect.
A UK study of 48,417 women found that significant weight gain after age 20 and late first pregnancy increase the risk of breast cancer. Women who experienced early first pregnancy were found to have greater weight gain during adulthood than those with a late first pregnancy.
A cohort study found associations between pre-pregnancy overweight, smoking during pregnancy, and formula-feeding with adverse cardiovascular health trajectories in early childhood. The study suggests that addressing these factors through interventions may optimize cardiovascular health in children.
The study estimates that expanded Medicare coverage for GLP-1RAs would increase access to these treatments and reduce obesity-related comorbidities. However, this would come with substantial costs over a decade, projected at $8 billion, highlighting the need for further price reductions and cost-saving strategies.
A study of 352 newborn pairs found that maternal childhood trauma can lead to excessive weight gain in male children as early as the first two months of life. This may increase future risk of obesity and diabetes, highlighting a potential intergenerational effect.
A new analysis of the SURMOUNT-1 trial found that around two-thirds of participants regained only 5% or less of their lowest weight over three years. The study suggests that most patients receiving tirzepatide had a relatively stable weight journey, with limited weight regain after reaching their nadir weight.
A new clinical trial found that oral semaglutide can significantly reduce cardiovascular events in people with type 2 diabetes and pre-existing cardiovascular disease. The medication decreased the risk of major cardiac events by 14% compared to placebo, with nonfatal myocardial infarction seeing the greatest reductions in risk.
A high-fat diet reduces neurotensin, a brain peptide that interacts with the dopamine network, leading to reduced pleasure in eating. Boosting neurotensin levels restores pleasure and promotes weight loss in mice, offering new avenues for addressing obesity.